VLC
EW icon

Van Leeuwen & Company’s Edwards Lifesciences EW Stock Holding History

Van Leeuwen & Company’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-12,922
Closed -$1.67M – 66
2021
Q4 		$1.67M Buy
+12,922
New +$1.51M 0.94% 37

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Van Leeuwen & Company's EW Position: Q1 2022 in Review

Van Leeuwen & Company sold out of Edwards Lifesciences (EW) in Q1 2022, closing a stake of 12,922 shares — an estimated $1.67M sold.

Van Leeuwen & Company first reported a position in EW in Q4 2021 and held it in 1 quarter. The position peaked at $1.67M in Q4 2021. 1,314 funds tracked by Wall St. Rank hold EW as of Q1 2022.

  • Van Leeuwen & Company reported no remaining Edwards Lifesciences position as of Q1 2022 after selling out during the quarter.
  • Van Leeuwen & Company sold 12,922 Edwards Lifesciences shares in Q1 2022, an estimated $1.67M.
  • Van Leeuwen & Company first reported a position in Edwards Lifesciences in Q4 2021 and held it in 1 quarter.
  • Van Leeuwen & Company's Edwards Lifesciences position peaked at $1.67M in Q4 2021.
  • 1,314 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2022.

Based on Van Leeuwen & Company's 13F filing for Q1 2022, filed 12 May 2022.